OncoStream claims 300,000 tests/yr but Germany's entire organised addressable volume is 174,240/yr (1.7x the whole market). Company-reported figure REJECTED for modelling; the independent 35-40% share estimate (~61-70k tests/yr) is retained instead.
handled: the company-reported figure is excluded from the model; the independent share estimate is used
A vendor cannot process more triage tests than the entire organised addressable volume. Company-reported figures must be checked against primary screening statistics.
CHK-03 · Competitor claim vs its own analyst share estimate WARN handledfails for Germany
handled: same figure as CHK-02, excluded from the model
The 300k claim should also be consistent with the 35-40% independent share estimate quoted in the same brief.
CHK-07 · Screened volume arithmetic FAIL open · needs a humanfails for Portugal
needs a human: correct the source value in overrides.yaml (with a reason) or re-run in Overdrive so the model can re-read it
Addressable = eligible x participation / 2 (biennial) x positivity, recomputed from components.
OncoStream claims 300,000 tests/yr but Germany's entire organised addressable volume is 174,240/yr (1.7x the whole market). Company-reported figure REJECTED for modelling; the independent 35-40% share estimate (~61-70k tests/yr) is retained instead.
handled: the company-reported figure is excluded from the model; the independent share estimate is used
A vendor cannot process more triage tests than the entire organised addressable volume. Company-reported figures must be checked against primary screening statistics.
CHK-03 · Competitor claim vs its own analyst share estimate WARN handledfails for Germany
handled: same figure as CHK-02, excluded from the model
The 300k claim should also be consistent with the 35-40% independent share estimate quoted in the same brief.
CHK-07 · Screened volume arithmetic FAIL open · needs a humanfails for Portugal
needs a human: correct the source value in overrides.yaml (with a reason) or re-run in Overdrive so the model can re-read it
Addressable = eligible x participation / 2 (biennial) x positivity, recomputed from components.
OncoStream claims 300,000 tests/yr but Germany's entire organised addressable volume is 174,240/yr (1.7x the whole market). Company-reported figure REJECTED for modelling; the independent 35-40% share estimate (~61-70k tests/yr) is retained instead.
handled: the company-reported figure is excluded from the model; the independent share estimate is used
A vendor cannot process more triage tests than the entire organised addressable volume. Company-reported figures must be checked against primary screening statistics.
CHK-03 · Competitor claim vs its own analyst share estimate WARN handledfails for Germany
handled: same figure as CHK-02, excluded from the model
The 300k claim should also be consistent with the 35-40% independent share estimate quoted in the same brief.
CHK-07 · Screened volume arithmetic FAIL open · needs a humanfails for Portugal
needs a human: correct the source value in overrides.yaml (with a reason) or re-run in Overdrive so the model can re-read it
Addressable = eligible x participation / 2 (biennial) x positivity, recomputed from components.
OncoStream claims 300,000 tests/yr but Germany's entire organised addressable volume is 174,240/yr (1.7x the whole market). Company-reported figure REJECTED for modelling; the independent 35-40% share estimate (~61-70k tests/yr) is retained instead.
handled: the company-reported figure is excluded from the model; the independent share estimate is used
A vendor cannot process more triage tests than the entire organised addressable volume. Company-reported figures must be checked against primary screening statistics.
CHK-03 · Competitor claim vs its own analyst share estimate WARN handledfails for Germany
handled: same figure as CHK-02, excluded from the model
The 300k claim should also be consistent with the 35-40% independent share estimate quoted in the same brief.
CHK-07 · Screened volume arithmetic FAIL open · needs a humanfails for Portugal
needs a human: correct the source value in overrides.yaml (with a reason) or re-run in Overdrive so the model can re-read it
Addressable = eligible x participation / 2 (biennial) x positivity, recomputed from components.
OncoStream claims 300,000 tests/yr but Germany's entire organised addressable volume is 174,240/yr (1.7x the whole market). Company-reported figure REJECTED for modelling; the independent 35-40% share estimate (~61-70k tests/yr) is retained instead.
handled: the company-reported figure is excluded from the model; the independent share estimate is used
A vendor cannot process more triage tests than the entire organised addressable volume. Company-reported figures must be checked against primary screening statistics.
CHK-03 · Competitor claim vs its own analyst share estimate WARN handledfails for Germany
handled: same figure as CHK-02, excluded from the model
The 300k claim should also be consistent with the 35-40% independent share estimate quoted in the same brief.
CHK-07 · Screened volume arithmetic FAIL open · needs a humanfails for Portugal
needs a human: correct the source value in overrides.yaml (with a reason) or re-run in Overdrive so the model can re-read it
Addressable = eligible x participation / 2 (biennial) x positivity, recomputed from components.
OncoStream claims 300,000 tests/yr but Germany's entire organised addressable volume is 174,240/yr (1.7x the whole market). Company-reported figure REJECTED for modelling; the independent 35-40% share estimate (~61-70k tests/yr) is retained instead.
handled: the company-reported figure is excluded from the model; the independent share estimate is used
A vendor cannot process more triage tests than the entire organised addressable volume. Company-reported figures must be checked against primary screening statistics.
CHK-03 · Competitor claim vs its own analyst share estimate WARN handledfails for Germany
handled: same figure as CHK-02, excluded from the model
The 300k claim should also be consistent with the 35-40% independent share estimate quoted in the same brief.
CHK-07 · Screened volume arithmetic FAIL open · needs a humanfails for Portugal
needs a human: correct the source value in overrides.yaml (with a reason) or re-run in Overdrive so the model can re-read it
Addressable = eligible x participation / 2 (biennial) x positivity, recomputed from components.
OncoStream claims 300,000 tests/yr but Germany's entire organised addressable volume is 174,240/yr (1.7x the whole market). Company-reported figure REJECTED for modelling; the independent 35-40% share estimate (~61-70k tests/yr) is retained instead.
handled: the company-reported figure is excluded from the model; the independent share estimate is used
A vendor cannot process more triage tests than the entire organised addressable volume. Company-reported figures must be checked against primary screening statistics.
CHK-03 · Competitor claim vs its own analyst share estimate WARN handledfails for Germany
handled: same figure as CHK-02, excluded from the model
The 300k claim should also be consistent with the 35-40% independent share estimate quoted in the same brief.
CHK-07 · Screened volume arithmetic FAIL open · needs a humanfails for Portugal
needs a human: correct the source value in overrides.yaml (with a reason) or re-run in Overdrive so the model can re-read it
Addressable = eligible x participation / 2 (biennial) x positivity, recomputed from components.
OncoStream claims 300,000 tests/yr but Germany's entire organised addressable volume is 174,240/yr (1.7x the whole market). Company-reported figure REJECTED for modelling; the independent 35-40% share estimate (~61-70k tests/yr) is retained instead.
handled: the company-reported figure is excluded from the model; the independent share estimate is used
A vendor cannot process more triage tests than the entire organised addressable volume. Company-reported figures must be checked against primary screening statistics.
CHK-03 · Competitor claim vs its own analyst share estimate WARN handledfails for Germany
handled: same figure as CHK-02, excluded from the model
The 300k claim should also be consistent with the 35-40% independent share estimate quoted in the same brief.
CHK-07 · Screened volume arithmetic FAIL open · needs a humanfails for Portugal
needs a human: correct the source value in overrides.yaml (with a reason) or re-run in Overdrive so the model can re-read it
Addressable = eligible x participation / 2 (biennial) x positivity, recomputed from components.
OncoStream claims 300,000 tests/yr but Germany's entire organised addressable volume is 174,240/yr (1.7x the whole market). Company-reported figure REJECTED for modelling; the independent 35-40% share estimate (~61-70k tests/yr) is retained instead.
handled: the company-reported figure is excluded from the model; the independent share estimate is used
A vendor cannot process more triage tests than the entire organised addressable volume. Company-reported figures must be checked against primary screening statistics.
CHK-03 · Competitor claim vs its own analyst share estimate WARN handledfails for Germany
handled: same figure as CHK-02, excluded from the model
The 300k claim should also be consistent with the 35-40% independent share estimate quoted in the same brief.
CHK-07 · Screened volume arithmetic FAIL open · needs a humanfails for Portugal
needs a human: correct the source value in overrides.yaml (with a reason) or re-run in Overdrive so the model can re-read it
Addressable = eligible x participation / 2 (biennial) x positivity, recomputed from components.
OncoStream claims 300,000 tests/yr but Germany's entire organised addressable volume is 174,240/yr (1.7x the whole market). Company-reported figure REJECTED for modelling; the independent 35-40% share estimate (~61-70k tests/yr) is retained instead.
handled: the company-reported figure is excluded from the model; the independent share estimate is used
A vendor cannot process more triage tests than the entire organised addressable volume. Company-reported figures must be checked against primary screening statistics.
CHK-03 · Competitor claim vs its own analyst share estimate WARN handledfails for Germany
handled: same figure as CHK-02, excluded from the model
The 300k claim should also be consistent with the 35-40% independent share estimate quoted in the same brief.
CHK-07 · Screened volume arithmetic FAIL open · needs a humanfails for Portugal
needs a human: correct the source value in overrides.yaml (with a reason) or re-run in Overdrive so the model can re-read it
Addressable = eligible x participation / 2 (biennial) x positivity, recomputed from components.
OncoStream claims 300,000 tests/yr but Germany's entire organised addressable volume is 174,240/yr (1.7x the whole market). Company-reported figure REJECTED for modelling; the independent 35-40% share estimate (~61-70k tests/yr) is retained instead.
handled: the company-reported figure is excluded from the model; the independent share estimate is used
A vendor cannot process more triage tests than the entire organised addressable volume. Company-reported figures must be checked against primary screening statistics.
CHK-03 · Competitor claim vs its own analyst share estimate WARN handledfails for Germany
handled: same figure as CHK-02, excluded from the model
The 300k claim should also be consistent with the 35-40% independent share estimate quoted in the same brief.
CHK-07 · Screened volume arithmetic FAIL open · needs a humanfails for Portugal
needs a human: correct the source value in overrides.yaml (with a reason) or re-run in Overdrive so the model can re-read it
Addressable = eligible x participation / 2 (biennial) x positivity, recomputed from components.
OncoStream claims 300,000 tests/yr but Germany's entire organised addressable volume is 174,240/yr (1.7x the whole market). Company-reported figure REJECTED for modelling; the independent 35-40% share estimate (~61-70k tests/yr) is retained instead.
handled: the company-reported figure is excluded from the model; the independent share estimate is used
A vendor cannot process more triage tests than the entire organised addressable volume. Company-reported figures must be checked against primary screening statistics.
CHK-03 · Competitor claim vs its own analyst share estimate WARN handledfails for Germany
handled: same figure as CHK-02, excluded from the model
The 300k claim should also be consistent with the 35-40% independent share estimate quoted in the same brief.